Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

776 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV Cohort.
Morawetz RA, Rizzardi GP, Glauser D, Rutschmann O, Hirschel B, Perrin L, Opravil M, Flepp M, von Overbeck J, Glauser MP, Ghezzi S, Vicenzi E, Poli G, Lazzarin A, Pantaleo G. Morawetz RA, et al. Among authors: perrin l. Eur J Immunol. 1997 Dec;27(12):3223-7. doi: 10.1002/eji.1830271220. Eur J Immunol. 1997. PMID: 9464809
Can HIV be eradicated?
Pantaleo G, Perrin L. Pantaleo G, et al. Among authors: perrin l. AIDS. 1998;12 Suppl A:S175-80. AIDS. 1998. PMID: 9633000 Review. No abstract available.
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
Rizzardi GP, De Boer RJ, Hoover S, Tambussi G, Chapuis A, Halkic N, Bart PA, Miller V, Staszewski S, Notermans DW, Perrin L, Fox CH, Lange JM, Lazzarin A, Pantaleo G. Rizzardi GP, et al. Among authors: perrin l. J Clin Invest. 2000 Mar;105(6):777-82. doi: 10.1172/JCI9079. J Clin Invest. 2000. PMID: 10727446 Free PMC article.
Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy.
Bart PA, Rizzardi GP, Tambussi G, Chave JP, Chapuis AG, Graziosi C, Corpataux JM, Halkic N, Meuwly JY, Munoz M, Meylan P, Spreen W, McDade H, Yerly S, Perrin L, Lazzarin A, Pantaleo G. Bart PA, et al. Among authors: perrin l. AIDS. 2000 Sep 8;14(13):1887-97. doi: 10.1097/00002030-200009080-00002. AIDS. 2000. PMID: 10997391 Clinical Trial.
The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia.
Pantaleo G, Demarest JF, Schacker T, Vaccarezza M, Cohen OJ, Daucher M, Graziosi C, Schnittman SS, Quinn TC, Shaw GM, Perrin L, Tambussi G, Lazzarin A, Sekaly RP, Soudeyns H, Corey L, Fauci AS. Pantaleo G, et al. Among authors: perrin l. Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):254-8. doi: 10.1073/pnas.94.1.254. Proc Natl Acad Sci U S A. 1997. PMID: 8990195 Free PMC article.
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M; Swiss HIV Cohort Study Group. Kaufmann GR, et al. Among authors: perrin l. Arch Intern Med. 2003 Oct 13;163(18):2187-95. doi: 10.1001/archinte.163.18.2187. Arch Intern Med. 2003. PMID: 14557216
Infrequent transmission of HIV-1 drug-resistant variants.
Yerly S, Jost S, Telenti A, Flepp M, Kaiser L, Chave JP, Vernazza P, Battegay M, Furrer H, Chanzy B, Burgisser P, Rickenbach M, Gebhardt M, Bernard MC, Perneger T, Hirschel B, Perrin L; Swiss HIV Cohort Study. Yerly S, et al. Among authors: perrin l. Antivir Ther. 2004 Jun;9(3):375-84. Antivir Ther. 2004. PMID: 15259900
776 results